Market Overview

Genzyme Hosting Investor Luncheon Friday In New York


Piper Jaffray has published a research report on Genzyme Corporation (NASDAQ: GENZ) following 3Q earnings results that came in below consensus estimates while still exceeding expectations for sales.

In the report, Piper Jaffray writes "Genzyme reported 3Q earnings below consensus but Cerezyme sales exceeded expectations, providing us some comfort in management's ability to return Cerezyme and Fabrazyme supply. 4Q EPS guidance implies 2011 EPS above $4.00, well above Street's $3.56. This potential upside combined with expectations for positive Phase III Campath data in MS could support a higher offer from SNY or another bidder; or at minimum, provide a floor in the low-to-mid $60s if SNY were to walk. The key now is execution, which has been lacking the past two years."

Piper Jaffray maintains its Neutral rating and $74 price target.

Genzyme Corporation closed yesterday at $72.11.

Posted-In: Genzyme Corporation Piper JaffrayAnalyst Color Analyst Ratings


Related Articles (GENZ)

View Comments and Join the Discussion!

Latest Ratings

TSCOPiper SandlerMaintains119.0
UNPBMO CapitalMaintains200.0
UNPArgus ResearchMaintains205.0
ISRGJP MorganMaintains665.0
EHTHRBC CapitalMaintains132.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at